• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Business Update

    10/28/21 9:15:00 AM ET
    $AMPE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPE alert in real time by email

    ENGLEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended September 30, 2021 and provide a corporate business update on Wednesday, November 10, 2021, at 4:30 pm EDT/ 2:30 pm MT.

    Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.)

    Conference Call & Webcast:

    Wednesday, November 10, 2021, 4:30 pm EDT / 2:30 pm MT

    Webcast Link: https://event.on24.com/wcc/r/3499388/60A0DA16A47D6B146B1AA111CA73357E   

    Conference Call (listen only): Canada dial-in number (Toll Free): 1 833 950 0062

              Canada dial-in number (Local): 1 226 828 7575

              United States: 1 844 200 6205

              United States (Local): 1 646 904 5544

              All other locations: +1 929 526 1599

              Access code: 385971

    In order to submit questions, participants must have internet connectivity, as questions will only be addressed via the webcast.  The conference call line will be in listen only mode.

    The conference call and webcast can also be accessed from the Investor Relations section of the Company's website at www.ampiopharma.com and will be archived there shortly after the live event.

    About Ampio Pharmaceuticals

    Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and may be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act (BPCIA).

    Forward Looking Statements

    Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter  into partnering arrangements,  clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

    Media Contact

    Katie Kennedy

    [email protected]

    610-731-1045

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-report-fiscal-2021-third-quarter-financial-results-and-provide-corporate-business-update-301411048.html

    SOURCE Ampio Pharmaceuticals, Inc.

    Get the next $AMPE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMPE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMPE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Ampio Pharmaceuticals Inc.

      15-12G - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

      4/15/24 4:15:06 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25 filed by Ampio Pharmaceuticals Inc.

      25 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

      4/4/24 1:32:03 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

      3/25/24 5:25:17 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care